Differential Effects of Typical and Atypical Neuroleptics on Mitochondrial Function In Vitro |
Josephine, S.
(Merrimack College, Department of Biology)
Napolitano, Modica (Merrimack College, Department of Biology) Lagace, Christopher-J. (Tufts University School of Medicine) Brennan, William-A. (Augusta Mental Health Institute) Aprille, June-R. (University of Richmond, Department of Biology) |
1 | Andreassen, O. A. and Jorgensen, H. A., Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats: Implications for tardive dyskinesia. Prog. Neurobiology, 61, 525-541 (2000) DOI ScienceOn |
2 | Beal, M. F., Aging, energy and oxidative stress in neurode-generative diseases. Ann. Neurol., 38, 357-3661 (1995) DOI PUBMED ScienceOn |
3 | Beasley, C. M., Jr., Hamilton, S. H., Crawford, A. M., Dellva, M. A., Tollefson, G. D., Tran, P. V., Blin, O., and Beuzen, J. N., Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur. Neuropsycho-pharmacol., 7, 125-137 (1997) DOI ScienceOn |
4 | Guth, P. S. and Spirtes, M. A., The phenothiazine tranquilizers: biochemical and biophysical actions. Int. Rev. Neurobio. l 7, 231-278 (1964) DOI |
5 | Maurer, I. and Molle, H-J., Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics. Mol. Cell Biochem., 174, 255-259 (1998) DOI ScienceOn |
6 | Schillevoort, I., de Boer, A., Herings, R. M., Roos, R. A., Jansen, P. A., and Leufkens, H. G., Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine. Ann. Pharmacother., 35, 1517-22 (2001) DOI ScienceOn |
7 | Roberts, R. C., Gaither, L. A., Gao, X-M., Kashyap, S. M., and Tammainga, C. A., Ultrastructural correlates of haloperidolinduced oral dyskinesis in rat striatum. Synapse, 20, 234-243 (1995) DOI ScienceOn |
8 | Grenell, R. G., Mendelson, J., and McElroy, W. D., Effects of chlorpromazine on metabolism in central nervous system. AMA Arch. Neurol. Psychiat., 73, 347-351 (1955) DOI |
9 | Sussman, N., Choosing an atypical antipsychotic. Int. Clin. Psychopharmacol., 17(3), 29-33 (2002) |
10 | Burkhardt, C., Kelly, J. P., Lim, Y-H., Filley, C. M., and Parker, W. D., Jr., Neuroleptic medications inhibit complex I of the electron transport chain. Ann. Neurol., 33, 512-517 (1993) DOI ScienceOn |
11 | Loft, S., Astrup, A., Buemann, B., and Poulsen, H. E., Oxidative DNA damage correlated with oxygen consumption in humans. FASEB J., 8, 534-537 (1994) DOI PUBMED |
12 | Tarsy, D. and Baldessarini, R. J., Tardive Dyskinesia. Ann. Rev. Med., 35, 605-623 (1984) DOI ScienceOn |
13 | Rand, D. M., Thermal habit, metabolic rate and the evolution of mitochondrial DNA. Trends Ecol. Evol., 9, 125-131 (1994) DOI ScienceOn |
14 | Goff, D. C., Tsai, G., Beal, M. F., and Coyle, J. T., Tardive dyskinesia and substrates of energy metabolism in CSF. Am. J. Psychiatr., 152, 1730-1736 (1995) DOI |
15 | Mitchell, I. J., Crossman, A. R., Liminga, U., Andren, P., and Gunne, L. M., Regional changes in 2-deoxyglucose uptake associated with neuroleptic-induced tardive dyskinesia in the cebus monkey. Mov. Disord., 7, 32-37 (1992) PUBMED |
16 | Schapira, A. H. V., Evidence for mitochondrial dysfunction in Parkinsons Disease - a critical appraisal. Mov. Disord., 9, 125-138 (1998) |
17 | Gallagher, C. H., Koch, J. H., and Mann, D. M., The effect of phenothiazine on the metabolism of rat liver mitochondria. Biochem. Pharmacol., 10, 369-372 (1965) |
18 | Green, D. R. and Reed, J. C., Mitochondria and apoptosis [Review]. Science, 281, 1309-1312 (1998) DOI PUBMED ScienceOn |
19 | Beal, M. F., Hyman, B.T., and Koroshetz, W., Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci., 16, 125-131 (1993) DOI ScienceOn |
20 | Lemmens, P., Breecher, M., and Van Baelen, B. A., Combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms. Acta Psychiatr. Scand., 99(3), 160-170 (1999) DOI ScienceOn |
21 | Chouinard, G., Ross-Chouinard, A., Annable, L., and Jones, B. D., The extrapyramidal symptom rating scale. Can. J. Neurol. Sci., 7, 233 (1980) |
22 | Balijepalli, S., Boyd, M. R., and Ravindranath, V., Inhibition of mitochondrial complex I by haloperidol: the role of thiol oxidation. Neuropharmacology, 38, 567-577 (1999) DOI ScienceOn |
23 | Glazer, W. M., Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J. Clin. Psychiatry, 61[suppl 3], 16-21 (2000) DOI PUBMED ScienceOn |
24 | Jeste, D. V., Lacro, J. P., Bailey, A., Rockwell, E., Harris, M. J., and Caligiuri, M. P., Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J. Am. Geriatr. Soc., 47(6), 716-719 (1999) DOI PUBMED |
25 | Tarsy, D., Baldessarini, R. J., and Tarazi, F. I., Effects of newer antipsychotics on extrapyramidal function. CNS Drugs, 16, 23-45 (2002) DOI ScienceOn |
26 | Byczkowski, J. Z. and Borysewicz, R., The action of chlorpromazine and imipramine on rat brain mitochondria. Gen. Pharmac., 10, 369-372 (1979) DOI ScienceOn |
27 | Prince, J. A., Yassin, M. S., and Oreland, L., Neurolepticinduced mitochondrial enzyme alterations in rat brain. J. Pharmacol. Exptl. Therapeut., 280, 261-267 (1997) |
28 | Casey, D. E., Extrapyramidal syndromes and new antipsychotic drugs: findings in patients and non-human primate models. Br. J. Psychiatry Suppl., 168(29), 32-39 (1996) |
29 | Modica-Napolitano, J. S., Joyal, J. L. , Ara, G., Oseroff, A. R., and Aprille, J. R., Mitochondrial toxicity of cationic photosensitizers for photochemotherapy. Cancer Res., 50, 7876-7881 (1990) PUBMED |
30 | Andreassen, O. A. and Jorgensen, H. A., The mitochondrial toxin 3-nitropropionic acid induces vacuous chewing movements in rats. Implications for tardive dyskinesia? Psychopharmacol., 119, 474-476 (1995) DOI |